ClinicalTrials.Veeva

Menu

Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing

P

Peking University

Status

Enrolling

Conditions

Prostate Cancer
Community-based Screening

Treatments

Other: No intervention

Study type

Observational

Funder types

Other

Identifiers

NCT07319923
BJCP-AI-UroScreen-2025-001

Details and patient eligibility

About

Prostate cancer is one of the most common malignancies in the male genitourinary system, and it is also the cancer with the fastest-growing incidence and mortality rates among men in China. Although prostate cancer screening can significantly reduce mortality, China has not yet established a well-developed screening system, which is one of the reasons why its mortality rate remains notably higher than that of Western countries. The primary objective of this project is to establish an efficient screening-diagnosis-treatment pathway, beginning with screening in community hospitals, followed by definitive diagnosis in secondary hospitals, and finally treatment in tertiary hospitals. Additionally, the project aims to achieve multi-institutional and multi-terminal sharing of disease information as well as dynamic monitoring and follow-up. The feasibility and effectiveness of this model will be validated through statistical analysis of the data.

Enrollment

3,000 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male community residents aged 50 years or older;

Life expectancy > 10 years and ECOG performance status of 0-2;

Permanent residents of Beijing who are willing to cooperate with researchers in the screening process, complete required tests and questionnaires, and participate in subsequent follow-up;

Support for the research project and provision of signed informed consent.

Exclusion criteria

  • 1)Presence of any other malignant tumor or pre-existing prostate malignancy; 2)Presence of prostatitis or active infection in other parts of the urinary system; 3)Inability to cooperate with the study procedures or other factors deemed unsuitable for participation in this study.

Trial contacts and locations

1

Loading...

Central trial contact

Zejin Ou

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems